Class 4 Caution in use-Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.

MHRA drug alert link:Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37 - GOV.UK

MHRA drug alert date:31/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email safety.uk@lambda-cro.com, or telephone  0800 0668348.

For stock control enquiries please email JPUK.Customerservice@jubl.com, or telephone 01233 552293

Class 2 recall-Flutiform 250/10mg (Alliance healthcare do not stock)

CD Pharma Ltd have notified the MHRA of an error on the outer carton of the product for the batches listed in this notification. While the total active content statement is correct, the delivered dose content statement is incorrect. The other details on the carton are correct.

Drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-flutiform-250-micrograms-slash-10-micrograms-per-actuation-pressurised-inhalation-suspension-cd-pharma-ltd-el-25-a-slash-35?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a726e5d4-c8e3-40a1-8762-ec99de3f74bb&utm_content=immediately

drug alert date: 24/07/25

Further Information

For all further enquiries please contact 01355 204 448 or email regaffairs@teleta.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Cencora Teams Raise £15,000 for Charity in Race the Sun Challenge!

Race the Sun Cheddar Gorge Challenge 2025 ☀️

Teams from Cencora Alliance Healthcare and Cencora Alloga have successfully raised and donated £15,000 for Action Medical Research following the Race the Sun Cheddar Gorge Challenge 2025 involving 30 team members from across the business. 

Participants pushed their limits in a day-long challenge involving:

    - 30 mile cycle (2,000 feet elevation) 🚴

    - 6 mile hike (1,200 feet elevation) 🚶

    - 1.2 mile canoe 🛶

All in the breathtaking surroundings of Cheddar Gorge in Somerset! On an extremely hot day (33.C) – really feeling the sun in the Race the Sun Challenge. All team members completed safely and were determined to reach the finish line to support vital medical research that saves children’s lives.

Action Medical Research is the UK’s leading charity dedicated to funding research to help sick and disabled babies, children and young people. For over 70 years, the charity has played a crucial role in driving medical progress, supporting research into rare and complex conditions that often receive little funding. The charity’s research has helped develop both the polio vaccine and ultrasound scanning in pregnancy, changing lives worldwide. 

Sam Unsworth, Head of Communications and RTS Challenger at Alliance Healthcare, said: “It was amazing to be part of a day filled with such strong team spirit and shared purpose. We’re so proud to be contributing to research that’s making a real difference for children and their families.” 

Lucy Holloway, Corporate Partnership and Event Management Executive, Action Medical Research said: “We are immensely grateful for the continued support of Alliance Healthcare UK. The funds that have been raised will go a long way in facilitating change for these children’s lives through important medical research.” 

The Race the Sun Cheddar Gorge Challenge 2025 showcased not only the physical endurance of the Alliance Healthcare and Alloga team members, but also the unwavering commitment to building a community united in supporting healthier futures through charitable fundraising and collective action. 

Class 2 recall-Zaditen eye drops

Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the medicinal product.

Drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zaditen-0-dot-25-mg-slash-ml-eye-drops-solution-laboratoires-thea-el-25-a-slash-34

drug alert date: 4/07/25

Further Information

For stock control enquiries please contact:

• For pharmacies supplied by a wholesaler, returns should be made via the wholesaler.
• For wholesalers, please contact Mawdsleys PreWholesaler (MPW) customer services using e-mail address customer.services@mpwpharma.co.uk
• For healthcare establishments: please arrange local destruction and make a claim through Mawdsleys PreWholesaler customer.services@mpwpharma.co.uk

For more information or medical information please call 0345 521 1290 (and select option 3) or e-mail thea-pharma@medinformation.co.uk

For stock control enquiries please email customer.services@mpwpharma.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Simvastatin 10mg Tablet, Crescent Pharma Ltd

Crescent Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of simvastatin 10 mg Tablets distributed by Alliance Healthcare UK.

MHRA Drug alert link: Class 4 Medicines Defect Notification: Simvastatin 10mg Tablet, Crescent Pharma Ltd, EL(25)A/33 - GOV.UK

MHRA drug alert date: 3/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email medinfo@crescentpharma.com, for reporting of side effects email safety@crescentpharma.com or telephone +44 1217901596.

For stock control enquiries please email Sean.McCaul@alliance-healthcare.co.uk

Class 4 caution in use-Erythromycin Stearate BP 250mg Tablets

Amdipharm UK Ltd has informed MHRA that the Patient information leaflet (PIL) in the cartons for the batch listed in this notification includes a superseded PIL.

MHRA Drug alert link: Class 4 Medicines Defect Notification: Erythromycin Stearate BP 250mg Tablets, Amdipharm UK Ltd, EL(25)A/32 - GOV.UK

MHRA drug alert date: 1/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email medicalinformation@advanzpharma.com, or telephone +44 (0) 208 588 9131

For stock control enquiries please email custcustomercare@advanzpharma.com or telephone 0208 588 9441

Class 3 recall-Tamoxifen 20mg Film-Coated Tablets

Wockhardt UK Limited is recalling a batch as a precautionary measure following the identification of a dissolution failure during stability testing.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-tamoxifen-20mg-film-coated-tablets-wockhardt-uk-ltd-el-25-a-slash-31?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=51a03b30-994a-4270-a2ee-77e56b55fcd8&utm_content=immediately

MHRA drug alert date: 30/06/25

Further Information

For medical information enquiries please email drug.safety@wockhardt.co.uk, or telephone 01978 661261 and ask for ‘drug safety’.

For stock control enquiries please email group_uk_csu@wockhardt.co.uk, or telephone 01978 661261and ask for ‘customer services’.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall – Omeprazole 20 mg/15 ml Oral Solution Active

We have received a Class 3 Recall from Glenmark Pharmaceuticals on Omeprazole 20 mg/15 ml Oral Solution

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-omeprazole-20-mg-slash-15-ml-oral-solution-glenmark-pharmaceuticals-europe-ltd-el-25-a-slash-30?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e78400fa-abcd-4b11-8293-0ab9b0eb4e68&utm_content=immediately

MHRA ref: DMRC-35139406

Reason: Glenmark Pharmaceuticals Europe Ltd is recalling a specific batch of Omeprazole Oral Solution as a precautionary measure due to an investigation following a customer complaint indicating precipitation and discoloration of the product in the bottles. A root cause has identified that this is a result of an inadequate assembly of the plunger stem and the cup which could lead to a premature mixing of the two components of the medicinal product.

Please can you ensure that your stores quarantine the product listed below. 

Further Information

For medical information enquiries please use the following options by phone +44 08004 580 383 or email medical_information@glenmarkpharma.com

For stock control enquiries please email orders.uk@glenmarkpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-PI Depo-Medrone 80mg/2mL suspension for injection

A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-depo-medrone-80-mg-in-2-ml-maxearn-limited-el-25-a-slash-29?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=bc49e601-5d15-4f12-b3b9-be4fddb3db61&utm_content=immediately

MHRA drug alert date 25/06/25

Further Information

For all medical information enquiries and information on this product, please email maxearnqa@maxearn.co.uk or telephone 01204 471 269.

For stock control enquiries please email maxearnqa@maxearn.co.uk or telephone 01204 471 269.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Kimmtrak 200 micrograms/mL concentrate for solution for infusion

Immunocore Limited is recalling the batches listed below as a precautionary measure. The recall is due to a decrease in potency identified during stability testing. All other stability test results remain within specification.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-kimmtrak-200-micrograms-slash-ml-concentrate-for-solution-for-infusion-immunocore-limited-el-25-a-slash-28?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=45800870-bf29-4be7-9270-c1a645ebf0b7&utm_content=immediately

MHRA drug alert date 25/06/25

Further Information

For all medical information enquiries and information on this product, please email medinfo.eu@immunocore.com, or telephone +442076645100 (local toll) or +00 800-74451111 (toll-free).

For stock control enquiries please email john.sandford@immunocore.com, or telephone +00353(0)858515258.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.